ITMCTR2200005632
Not yet recruiting
未知
Randomized controlled trial and metabolomic mechanism of Lingbao Huxin Pill in the treatment of stable angina (Qi deficiency and blood stasis syndrome)
Conditionsstable angina
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- stable angina
- Sponsor
- Shuguang Hospital of Shanghai University of Traditional Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Inclusion criteria for the stable angina group
- •(1\) Meet the western medical diagnostic standards for stable type angina of coronary heart disease;
- •(2\) Meet the TCM dialectical standards for qi deficiency and blood stasis;
- •(3\) Patients with angina attacks 2 or more times a week;
- •(4\) The Canadian Cardiovascular Society (CCS) graded angina with gradeS I.\-III.;
- •(5\) Age 18\-80 years old (including 18 and 80 years old);
- •(6\) Sign the informed consent form.
- •2\.Criteria for inclusion in the acute myocardial infarction group
- •(1\) Meet the diagnostic criteria of Western medicine for acute myocardial infarction;
- •(2\) Meet the TCM dialectical standards for qi deficiency and blood stasis;
Exclusion Criteria
- •(1\) Pregnant, planned pregnancy or lactating women;
- •(2\) Those with serious cardiovascular diseases such as refractory heart failure, cardiogenic shock, and severe valvular heart disease;
- •(3\) Chest pain caused by lesions other than coronary artery disease, such as psychosis, severe neurosis, hyperthyroidism, biliary syndrome, gastric and esophageal reflux, aortic dissection, etc.;
- •(4\) Complicated with uncontrolled grade III hypertension (systolic blood pressure \= 180mmHg and/or diastolic blood pressure \=110mmHg), severe arrhythmias;
- •(5\) Severe respiratory diseases such as severe pulmonary insufficiency (PaO2\<60mmHg).
- •(6\) Patients with severe liver and kidney diseases such as hepatic insufficiency (the level of alanine aminotransferase or aspartate aminotransferase is more than 2 times higher than normal), renal insufficiency (creatinine level is more than 2 times higher than normal);
- •(7\) There are other serious diseases or conditions such as malignant tumors, severe anemia, and severe renal artery stenosis;
- •(8\) Patients who are allergic to the components of the test drug and have severe allergic constitutions;
- •(9\) Those who have participated in clinical research of other drugs in the past 2 months;
- •(10\) Recently, researchers with infections, traumas, etc. have judged that they cannot participate in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Metabolic effects of adding Topiramate on Aripiprazole in bipolar patients under age 18IRCT20200606047668N1Esfahan University of Medical Sciences38
Withdrawn
Phase 3
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on CancerCancerOverall SurvivalNCT02201381Health Clinics Limited
Recruiting
Phase 1
Study the effect of CAPRIDIN in the metabolic treatment of drug-resistant epilepsyIRCT20170315033086N11Shahid Beheshti University of Medical Sciences10
Not yet recruiting
Not Applicable
Multicenter trial of effects for glucometabolism, platelet activation marker and inflammatory marker by single or combinathin therapy with tofogliflozin and anagliptin in type 2 diabetic patientstype 2 diabetes mellitusJPRN-UMIN000028634Kansai Medical University100
Completed
Not Applicable
Randomized, controlled trial of the clinical effect of selecrive SGLT2 blocker, ipragliflozin, and DPP-4 blocker in type 2 diabetic patients with NAFLD/NASH.- multicenter studytype 2 diabetic patients with NAFLD/NASHJPRN-UMIN000015727Saga University55